Company name:

Eagle Pharmaceuticals Inc

  • IPO SHARE PRICE:
    $15.00
  • IPO DATE:
    February 12, 2014
  • TICKER:
    EGRX
  • MAIN STOCK EXCHANGE:
    NASDAQ
  • CURRENT HQ LOCATION:
    50 Tice Boulevard Suite 315 Woodcliff Lake NJ 07677
  • FISCAL YEAR END:
    December 31
  • INCORPORATION JURISDICTION:
    DE
  • ORGANIZED AS THE FOLLOWING LEGAL TYPE:
    Corporation
  • Investor Relations Webpage:
    Coming soon!
  • TAX RATE:
    USA federal corporate nominal income tax rate is 21%

Short Description

Eagle Pharmaceuticals Inc

We are working hard and as soon as possible to provide company description soon. Feel free to reach out to request it sooner: improve@real-clear-investing.com

Statement of Cash Flow

Quarterly Annual
(USD in thousand)
Selected Year:
31-Dec
2020
OPERATING ACTIVITIES
Cash received and spent on operating activites of business — buying materials, paying salaries, receiving payments from clients, etc
39.7% - Stock-based compensation
19.2% - Net income (loss)
18.3% - Prepaid expenses and other assets
8.5% - (Gain) loss on revaluation of equity investment
4.7% - Fair value adjustments on settled accelerated share repurchase agreement
4.3% - Amortization of intangible assets
2.0% - Amortization of right-of-use assets
1.4% - Depreciation
1.3% - Accounts payable
0.7% - Amortization of debt issuance costs
SOURCEs
4.3% 18.3% 8.5% 4.7% 39.7% 19.2%
100 %
0%
USES
79.3% 5.0% 7.1% 3.7%
7.1% - Accrued expenses and other liabilities
5.0% - Accounts receivable
3.7% - Other assets
2.4% - Deferred income taxes
2.4% - Inventory
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Net income (loss)
$45,679
$45,679
$45,679
 $31,903 $14,313 $11,989 $11,989 $32,228
Depreciation
$45,679
$45,679
$45,679
 1,155 2,131 872 872 864
Amortization expense
$45,679
$45,679
$45,679
 2,515 2,520 - - -
Amortization of intangible assets
-
-
-
 2,515 2,520 2,666 2,666 2,668
Amortization of right-of-use assets
-
-
-
 - 1,159 1,228 1,228 992
Amortization of debt issuance costs
$45,679
$45,679
$45,679
 376 480 419 419 472
Stock-based compensation
$45,679
$45,679
$45,679
 19,082 21,998 24,756 24,756 25,284
Deferred income taxes
$45,679
$45,679
$45,679
 (2,468) 152 (1,511) (1,511) 640
Asset impairments
$45,679
$45,679
$45,679
 2,704 - - - -
(Gain) loss on sale of fixed assets
$45,679
-
-
 - - - - -
(Gain) loss on sale of assets
-
$45,679
$45,679
 - - - - -
Gain on sale of diclofenac-misoprostol
$45,679
-
-
 - - - - -
(Gain) loss on revaluation of equity investment
-
-
-
 - - 5,300 5,300 (9,600)
Change in fair value of contingent consideration
$45,679
$45,679
$45,679
 (763) - - - -
Fair value adjustments on settled accelerated share repurchase agreement Fair value adjustments on settled accelerated share repurchase agreement
-
-
-
 - - 2,962 2,962 11,848
Non-cash restructuring costs
-
$45,679
$45,679
 5,769 - - - -
Accounts receivable
$45,679
$45,679
$45,679
 (12,665) 18,481 (3,113) (3,113) 4,328
Inventory
$45,679
$45,679
$45,679
 (5,556) 1,739 (1,509) (1,509) (5,956)
Prepaid expenses and other assets
$45,679
$45,679
$45,679
 4,838 (4,841) 11,386 11,386 56,640
Other assets
-
$45,679
$45,679
 (570) (599) (2,325) (2,325) (9,300)
Accounts payable
$45,679
$45,679
$45,679
 (2,064) (4,455) 806 806 (27,200)
Accrued expenses and other liabilities
$45,679
$45,679
$45,679
 8,128 4,067 (4,429) (4,429) (2,052)
Deferred revenue
$45,679
$45,679
$45,679
 - - - - -
Net cash provided by (used in) operating activities
$45,679
$45,679
$45,679
 $52,384 $55,986 $49,497 $49,497 $79,040
Selected Year:
31-Dec
2020
INVESTING ACTIVITIES
Cash spent on acquiring plant, equipment and other businesses, cash recei0 from sale of plant, equipment and subsidiaries as well cash parked temporarily in different securities - government bonds typically
SOURCEs
0%
100 %
0%
USES
4.1% 95.9%
95.9% - (Purchases) sale of equity securities
4.1% - (Purchase) sale of property and equipment
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Purchases of marketable securities
$45,679
$45,679
$45,679
 - - - - -
Maturities of marketable securities
$45,679
$45,679
$45,679
 - - - - -
(Purchases) sale of equity securities
-
-
-
 - - (17,500) (17,500) -
(Purchase) sale of property and equipment
$45,679
$45,679
$45,679
 (133) (777) (747) (747) (680)
Acquisition of Docetaxel
$45,679
$45,679
$45,679
 - - - - -
Acquisition of Eagle Biologics net of cash
$45,679
$45,679
$45,679
 - - - - -
Payment for Ryanodex intangible asset
$45,679
$45,679
$45,679
 - - - - -
Sale of Diclofenac-Misoprostol
$45,679
$45,679
$45,679
 - - - - -
Net cash provided by (used in) investing activities
$45,679
$45,679
$45,679
 ($133) ($777) ($18,247) ($18,247) ($680)
Selected Year:
31-Dec
2020
FINANCING ACTIVITIES
Items in this group are concerned with borrowing funds, repaying debt, issuing equity, buying back shares, etc.
72.6% - Borrowing under Revolving Credit Facility
2.4% - Proceeds from issuance of common stock upon exercise of stock options
SOURCEs
25.0% 72.6%
100 %
0%
USES
72.6% 3.3% 23.1%
72.6% - Repayment of Revolving Credit Facility
23.1% - Repurchases of common stock
3.3% - Repayment of debt
1.0% - Employee withholding taxes paid upon excercise of stock options
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Proceeds from issuance of common stock upon exercise of stock options Proceeds from issuance of common stock upon exercise of stock options
$45,679
$45,679
$45,679
 8,615 260 3,654 3,654 12,396
Borrowing under Revolving Credit Facility
-
-
-
 - - 110,000 110,000 -
Repayment of Revolving Credit Facility
-
-
-
 - - (110,000) (110,000) -
Payment of debt principal
$45,679
$45,679
$45,679
 (3,750) - - - -
Repayment of debt
-
-
$45,679
 (3,750) (6,000) (5,000) (5,000) (8,000)
Long-term borrowing
-
-
$45,679
 - - - - -
Borrowing
$45,679
-
-
 - - - - -
Debt fees and financing costs
$45,679
-
$45,679
 - (326) - - -
Contingent consideration payment
-
$45,679
$45,679
 (15,000) - - - -
Employee withholding taxes paid upon excercise of stock options Employee withholding taxes paid upon excercise of stock options
-
-
-
 - (198) (1,525) (1,525) (6,100)
Payments for employee net option exercises
-
$45,679
$45,679
 (4,877) - - - -
Repurchases of common stock
$45,679
$45,679
$45,679
 (73,105) (17,961) (34,999) (34,999) (28,000)
Net cash provided by (used in) financing activities
$45,679
$45,679
$45,679
 ($88,117) ($24,225) ($37,870) ($37,870) ($24,464)
Selected Year:
31-Dec
2020
NET CHANGE IN CASH
Grand Total for sum of cash flows coming from operations, investing and financing
($6,620,000)
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Cash and equivalents - Beginning of period
$45,679
$45,679
$45,679
 $114,657 $78,791 $109,775 - $358,724
(Decrease) increase in cash and cash equivalents
$45,679
$45,679
$45,679
 (35,866) 30,984 (6,620) - 53,896
Cash and equivalents - End of period
$45,679
$45,679
$45,679
 $78,791 $109,775 $103,155 - $412,620